Research progress in membrane fusion-based hybrid exosomes for drug delivery systems

Anqi Liu; Gang Yang; Yuehua Liu; Tingjiao Liu

doi:10.3389/fbioe.2022.939441

Research progress in membrane fusion-based hybrid exosomes for drug delivery systems

Front Bioeng Biotechnol. 2022 Aug 16:10:939441. doi: 10.3389/fbioe.2022.939441. eCollection 2022.

Authors

Anqi Liu^{1

2

3}, Gang Yang^{1

2}, Yuehua Liu^{1

2}, Tingjiao Liu^{2

3}

Affiliations

¹ Department of Orthodontics, Shanghai Stomatological Hospital and School of Stomatology, Fudan University, Shanghai, China.
² Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China.
³ Department of Oral Pathology, Shanghai Stomatological Hospital and School of Stomatology, Fudan University, Shanghai, China.

Abstract

Liposomes are the earliest and most widely used nanoparticles for targeted drug delivery. Exosomes are nanosized membrane-bound particles and important mediators of intercellular communication. Combining liposomes and exosomes using various membrane fusion methods gives rise to a novel potential drug delivery system called membrane fusion-based hybrid exosomes (MFHE). These novel MFHEs not only exhibit potential advantageous features, such as high drug loading rate and targeted cellular uptake via surface modification, but are also endowed with high biocompatibility and low immunogenicity. Here, we provide an overview of MFHEs' various preparation methods, characterization strategies, and their applications for disease treatment and scientific research.

Keywords: disease diagnosis; disease treatment; drug delivery system; exosomes; liposomes; membrane fusion-based hybrid exosomes.

Publication types

Review